Efficacy and safety of ertugliflozin: results of the VERTIS CV sub-study in patients receiving a stable dose of insulin


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. The progressive course of type 2 diabetes mellitus (DM2) often necessitates combination therapy with oral antihypergly-cemic agents, and eventually insulin, alone or in combination with other antidiabetic agents, may become necessary to maintain glucose levels. Objective. Reporting of results of the VERTIS CV sub-study. Methods. VERTIS CV is a randomized, double-blind, parallel group, placebo-controlled study of ertugliflozin cardiovascular outcomes. Patients were randomly assigned to placebo and ertugliflozin at a dose of 5 or 15 mg/day. A sub-study included patients receiving a stable dose of insulin >20 IU/day. Of8246patients randomized to VERTIS CV, 1065 were included in the sub-study (68.2% male patients, mean age 64.8±7.8 years; DM2 duration: 16.7±9.0 years; glycosylated hemoglobin (HbA1c): 8.4±1.0%). The main end point was the change in HbA1c level from baseline at 18 weeks. Secondary endpoints were changes in fasting plasma glucose (FPG) level, body weight (BW), proportion of patients with HbA1c <7%, systolic blood pressure (SBP), diastolic blood pressure (DBP), and insulin dose. Results. At 18 week, the mean change from baseline in HbA1c level with ertugliflozin 5 and 15 mg versus placebo (95% CI) was -0.58% (-0.71-0.44) and -0.65% (-0.78--0.51), respectively (P<0.001 for both). Ertugliflozin significantly reduced FPG, BW, and SBP. In women, the incidence of genital fungal infections was higher with ertugliflozin (3.5%) compared with placebo (0.0%). The frequency of symptomatic hypoglycemia was similar in the treatment groups. Conclusion. The addition of ertugliflozin to insulin improved glycemic control, BW, and SBP at 18 weeks in DM2 patients with atherosclerotic cardiovascular disease compared with placebo.

Full Text

Restricted Access

About the authors

Maria S. Novikova

Endocrinological Dispensary of the Moscow Healthcare Department

Email: citrus7474@mail.ru
Cand. Sci. (Med.), Nephrologist

O. M Koteshkova

Endocrinological Dispensary of the Moscow Healthcare Department

M. B Antsiferov

Endocrinological Dispensary of the Moscow Healthcare Department

References

  1. Lingvay I., Greenberg M., Gallo S., et al. Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substud. Randomized Controlled Trial. Diab Obes Metab. 2021;23(7):1640-51. doi: 10.1111/dom.14385.
  2. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020. Diab Care. 2020;43:S98-110. doi: 10.2337/dc20-S009.
  3. Davies M.J., D'Alessio D.A., Fradkin J., et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diab Care. 2018;41:2669-701. doi: 10.2337/dci18-0033.
  4. Filippas-Ntekouan S., Filippatos T.D., Elisaf M.S. SGLT2 inhibitors: are they safe? Postgrad. Med. 2018;130:72-82. doi: 10.1080/00325481.2018.1394152.
  5. Hsia D.S., Grove O., Cefalu W.T. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diab Obes. 2017;24:73-9. Doi: 10.1097/ MED.0000000000000311.
  6. Thomas M.C. Type 2 diabetes and heart failure: challenges and solutions. Curr Cardiol Rev 2016;12:249-55. doi: 10.2174/1573403x1266 6160606120254.
  7. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis. 2012;60:850-86. doi: 10.1053/j.ajkd.2012.07.005.
  8. Zinman B., WannerC., LachinJ.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-28. doi: 10.1056/NEJMoa1504720.
  9. Neal B., Perkovic V., Mahaffey K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-57. doi: 10.1056/NEJMoa1611925.
  10. Wiviott S.D., Raz I., Bonaca M.P, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347-57. doi: 10.1056/ NEJMoa1812389.
  11. Packer M., Anker S.D., Butler J., et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413-24. doi: 10.1056/NEJMoa2022190.
  12. Perkovic V, Jardine M.J., Neal B., et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295-306. doi: 10.1056/NEJMoa1811744.
  13. Heerspink H.J.L, Stefa nsson B.V., Correa-Rotter R., et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436-46. doi: 10.1056/NEJMoa2024816.
  14. Cannon C.P, Pratley R., Dagogo-Jack S., et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383:1425-35. doi: 10.1056/NEJMoa2004967
  15. Cosentino F, Cannon C.P, Cherney D.Z.I., et al. Efficacy ofertugliflozin on heart failurerelated events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: Results of the VERTIS CV trial. Circulation. 2020;142:2205-15. doi: 10.1161/CIRCULATI0NAHA.120.050255.
  16. Cherney D.Z.I., Charbonnel B., Cosentino F, et al. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetol. 2021. [in press]
  17. Blonde L, Brunton S.A., Chava P, et al. Achievement of Target A1C by U.S. Type 2 Diabetes Patients Treated With Basal Insulin in Both (Randomized Controlled Trials and Clinical Practice. Diab Spectr. 2019;32:93-103. doi: 10.2337/ds17-0082.
  18. Meneghini L.F, Sullivan S.D., Oster G., et al. A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first-generation basal insulin analogues in insulin-naive adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control study. Diab 0bes Metab. 2020;22(11):2004-2012. Doi: 10.1111/ dom.14152.
  19. Dalal M.R., Grabner M., Bonine N., et al. Are patients on basal insulin attaining glycemic targets? Characteristics and goal achievement of patients with type 2 diabetes mellitus treated with basal insulin and physicianperceived barriers to achieving glycemic targets. Diab Res Clin Pract. 2016;121:17-26. doi: 10.1016/j.diabres.2016.08.004.
  20. Cannon C.P, McGuire D.K., Pratley R., et al. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J. 2018;206:11-23. Doi: 10.1016/j. ahj.2018.08.016.
  21. Petersen M.C., Shulman G.I. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018;98:2133-223. Doi: 10.1152/ physrev.00063.2017.
  22. Vallon V, Thomson S.C. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetol. 2017;60:215-25. doi: 10.1007/s00125-016-4157-3.
  23. Neal B., Perkovic V., de Zeeuw D., et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diab Care. 2015;38:403-11. doi: 10.2337/dc14-1237.
  24. Rosenstock J., Jelaska A., Zeller C., et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diab 0bes Metab. 2015;17:936-48. doi: 10.1111/dom.12503.
  25. Rosenstock J., Jelaska A., Frappin G., et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diab Care. 2014;37:1815-23. doi: 10.2337/dc13-3055.
  26. Wilding J.P, Woo V., Soler N.G., et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156:405 15. doi: 10.7326/0003-4819-156-6201203200-00003
  27. Wilding J.P., Woo V., Rohwedder K., et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diab Obes Metab. 2014;16:124-36. doi: 10.1111/dom.12187.
  28. Vasilakou D., Karagiannis T, Athanasiadou E., et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and metaanalysis. Ann Intern Med. 2013;159:262-74. doi: 10.7326/0003-4819-159-4-201308200-00007.
  29. European Medicines Agency. SteglatroTM summary of product characteristics. URL: https://www.ema.europa.eu/en/documents/product-information/steglatro-eparproduct-information_en.pdf. Accessed December 15, 2020.
  30. Food and Drug Administration. SteglatroTM prescribing information. URL: https://www.acces5eata.fda.gov/drugsutfda_doc5/label/2017/209803s000lbl.pdf. Accessed December 15, 2020.
  31. Dagogo-Jack S., Liu J., Eldor R., et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study. Diab Obes Metab. 2018;20:530-40. doi: 10.1111/dom.13116.
  32. Grunberger G., Camp S., Johnson J., et al. Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study. Diab Ther. 2018;9:49-66. doi: 10.1007/s13300-017-0337-5.
  33. Hollander P., Liu J., Hill J., et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: the VERTIS SU randomized study. Diab Ther. 2018;9:193-207. doi: 10.1007/s13300-017-0354-4.
  34. Miller S., Krumins T., Zhou H., et al. Ertugl_/zin and sitagliptin co-initiation in patients with type 2 diabetes: the VERTIS SITA randomized study. Diab Ther 2018;9:253-68. doi: 10.1007/s13300-017-0358-0.
  35. Pratley R.E., Eldor R., Raji A., et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial. Diab Obes Metab 2018;20:1111-20. doi: 10.1111/dom.13194.
  36. Rosenstock J., Frias J., Páll D., et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diab Obes Metab. 2018;20:520-29. doi: 10.1111/dom.13103
  37. Terra S.G., Focht K., Davies M., et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately 5/ntr/lled with diet and exercise alone. Diab Obes Metab. 2017;19:721-28. Doi: 10.1111/ d/m.12888.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies